SCHEMBL2214178

SCHEMBL2214178

NCc1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc5c4oc4ccccc45)cc4ccnn34)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
PLAU P00749 4/20 0.39
PLG P00747 4/20 0.39
KLK1 P06870 3/20 0.39
PLAT P00750 2/20 0.39
PRSS1 P07477 2/20 0.39
F2 P00734 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.36
KLK6 Q92876 2/20 0.36
KLKB1 P03952 1/20 0.36
MAPT P10636 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
P2RX3 P56373 1/20 0.35
PCSK9 Q8NBP7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215322 0.95 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2213715 0.94 SMN1; SMN2 (0.38) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2215134 0.94 LOXL2 (0.38) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2211331 0.92 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2214233 0.92 DNMT1 (0.42) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2216183 0.92 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2213958 0.92 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2214452 0.91 ROCK2 (0.39) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2214689 0.91 NAMPT (0.34) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL2253400 0.91 MEN1 (0.35) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 KDM4E 3784/4885ALDH1A1 1334/4885HPGD 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.